ReviewInternational journal of molecular sciences2020
Diagnostic and Therapeutic Implications of microRNAs in Non-Small Cell Lung Cancer.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- The importance microRNAs as a biomarker in lung cancer.Acta bio-medica : Atenei Parmensis · 2023Pooled it
- High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer.Annals of medicine · 2021Pooled it
- Human biomarker navigator.iMeta · 2026Review
- Article
- Research progress of MicroRNA in lung cancer.Discover oncology · 2026Review
- Stage- and smoking-associated microRNA expression in lung adenocarcinoma.Translational lung cancer research · 2025Article
- miR-28-5p and miR-708-5p Share a Common Seed with Different Functions in Lung Cancer Patients.International journal of molecular sciences · 2025Article
- miR-224-5p Suppresses Non-Small Cell Lung Cancer via IL6ST-Mediated Regulation of the JAK2/STAT3 Pathway.Thoracic cancer · 2025Article
- Bone sialoprotein facilitates anoikis resistance in lung cancer by inhibiting miR-150-5p expression.Journal of cellular and molecular medicine · 2024Article
- miR-200-mediated inactivation of cancer-associated fibroblasts via targeting of NRP2-VEGFR signaling attenuates lung cancer invasion and metastasis.Molecular therapy. Nucleic acids · 2024Article
- Hsa_circ_0004214 involved in the epithelial-mesenchymal transition induced by beryllium sulfate through modulating JAK-STAT signaling pathway.Toxicology research · 2024Article
- MiR-760 exerts a critical regulatory role in glioma proliferation, migration, and invasion by modulating MMP2 expression.Journal of Cancer · 2024Article
- miR-199a and miR-199b facilitate diffuse gastric cancer progression by targeting Frizzled-6.Scientific reports · 2023Article
- Role of miR‑200 family in brain metastases: A systematic review.Molecular and clinical oncology · 2023Article
- In silico Identification of Hypoxic Signature followed by reverse transcription-quantitative PCR Validation in Cancer Cell LinesIranian biomedical journal · 2023Article
- Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.EXCLI journal · 2023Review
- MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.Medicine · 2022Article
- Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19.Seminars in cancer biology · 2022Review
- Article
- Long noncoding RNA regulatory factor X3- antisense RNA 1 promotes non-small cell lung cancer via the microRNA-577/signal transducer and activator of transcription 3 axis.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
microRNAs (miRNAs), endogenous suppressors of target mRNAs, are deeply involved in every step of non-small cell lung cancer (NSCLC) development, from tumor initiation to progression and metastasis. They play roles in cell proliferation, apoptosis, angiogenesis, epithelial-to-mesenchymal transition, migration, invasion, and metastatic colonization, as well as immunosuppression. Due to their versatility, numerous attempts have been made to use miRNAs for clinical applications. miRNAs can be used as cancer subtype classifiers, diagnostic markers, drug-response predictors, prognostic markers, and therapeutic targets in NSCLC. Many challenges remain ahead of their actual clinical application; however, when achieved, the use of miRNAs in the clinic is expected to enable great progress in the diagnosis and treatment of patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.